Veracyte Q3 2026 net income jumps 65% to $31.5 million

Bitget2026/11/04 21:24

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Veracyte’s third-quarter 2026 net income climbed 65% year-over-year to $31.5 million, while revenue rose 15% to $151.8 million.
Operating income fell 28% year-over-year to $16.57 million.
The board authorized up to $100 million in common stock repurchases; the business acquired bladder cancer testing developer Convergent Genomics.
Full-year 2026 revenue guidance narrowed to $590 million–$593 million from $590 million–$596 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611041605PRIMZONEFULLFEED9870413) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Veracyte Q3 2026 net income jumps 65% to $31.5 million

You may also like

Crypto prices